Duality Biotherapeutics, Inc. (HKG:9606)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Research and Development of New Drugs	1.85B	1.94B	1.79B	1.60M
Total	1.85B	1.94B	1.79B	1.60M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
China	1.85B	1.94B	1.79B	1.60M
Total	1.85B	1.94B	1.79B	1.60M

Data Source: S&P Global Market Intelligence Last updated: Sep 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 10, 2026

Data Sources Report a data error